09/5/0562

## **Refine Search**

#### Search Results -

Terms	Documents	
L10 and phenotyp\$ near5 response\$	2	

US Pre-Grant Publication Full-Text Database US Patents Full-Text Database US OCR Full-Text Database

Database:


EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index

IBM Technical Disclosure Bulletins

Search:

11	
	E









### **Search History**


DATE: Thursday, January 06, 2005 Printable Copy Create Case

Set Name side by side	Query	<u>Hit</u> Count	Set Name result set
DB=F	PGPB, USPT, USOC, EPAB, JPAB, DWPI, TDBD; PLUR=YES; OP=OR		
<u>L11</u>	L10 and phenotyp\$ near5 response\$	2	L11
<u>L10</u>	enzyme\$ near5 (agonist\$ or antagonist\$) near10 (assay\$ or screen)	186	L10
<u>L9</u> L8	L8 and mammalian	. 39	L9
<u>L8</u>	L5 and enzym\$ near5 activit\$	41	L8
<u>L7</u>	L5 and phosphorylation	49	$\overline{\text{L7}}$
<u>L6</u>	L5 and (PKC or p21ras or pp60src or ornithine near decarboxylase or protein near kinase\$)	33	<u>L6</u>
L5	L4 and phenotyp\$ near5 respons\$	63	L5
L4	cell near5 based near5 (assay\$ or screen\$) near10 (inhibit\$ or activat\$)	2218	$\overline{L4}$
$\frac{L4}{L3}$	L2 and phenotype\$ near5 response\$	8	$\overline{L3}$
<u>L2</u>	(assay or screen) near5 (direct\$ or specifi\$) near5 (inhib\$ or activat\$ or bind\$) near5 enzyme\$	498	<u>L2</u>
<u>L1</u>	(direct\$ or specifi\$) near5 (inhib\$ or activat\$ or bind\$) near5 enzyme\$	8418	<u>L1</u>

END OF SEARCH HISTORY

## Generate Collection Print

### Search Results - Record(s) 1 through 63 of 63 returned.



#### C12P021/02 C12N005/06.

13. 20040005545. 21 Feb 03. 08 Jan 04. Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus. Fouchier, Ronaldus Adrianus Maria, et al. 435/5; 424/211.1 435/235.1 C12Q001/70 A61K039/155 C12N007/00. 14. 20040001831. 26 Jun 02. 01 Jan 04. Methods and compositions for the diagnosis and treatment of demyelinating inflammatory disorders. Rottman, James B., et al. 424/146.1; 424/85.2 435/7.21 514/11 514/171 514/291 A61K038/20 A61K039/395 A61K031/573 A61K031/4745 G01N033/567. 15. 20030232061. 21 Feb 03. 18 Dec 03. Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus. Fouchier, Ronaldus Adrianus Maria, et al. 424/211.1; 435/235.1 A61K039/155 C12N007/00. 16. 20030211475. 05 Sep 01. 13 Nov 03. Methods for identifying pathway-specific reporters and target genes, and uses thereof. Roberts, Christopher J., 435/6; 702/20 C12Q001/68 G06F019/00 G01N033/48 G01N033/50. 17. 20030195461. 06 Nov 02. 16 Oct 03. Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation. Demopulos, Gregory A., et al. 604/59; 514/1 A61K031/00 A61M031/00. 18. 20030175208. 16 Oct 02. 18 Sep 03. Neutrokine-alpha and neutrokine-alpha splice variant. Yu, Guo-Liang, et al. 424/1.49; 424/1.69 A61K051/00. 19. 20030170891. 19 Sep 02. 11 Sep 03. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA). McSwiggen, James A.. 435/366; 514/263.21 514/44 514/81 536/23.1 544/243 544/244 544/276 544/277 A61K048/00 C07H021/02 A61K031/675 A61K031/52 C07D473/24. 20. 20030159162. 11 Mar 03. 21 Aug 03. Methods of using transporter-like molecules to treat pain and pain-related disorders. Goodearl, Andrew D. J., et al. 800/8; 435/320.1 435/325 435/69.1 435/7.2 530/350 530/388.22 536/23.5 G01N033/53 G01N033/567 A01K067/00 C07H021/04 C12P021/02 C12N005/06 C07K014/47. □ 21. 20030152917. 15 Jan 03. 14 Aug 03. Method of managing the chemotherapy of patients who are HIV positive based on the phenotypic drug sensitivity of human HIV strains. de Bethune, Marie-Pierre, et al. 435/5; 435/456 702/20 C12Q001/70 G06F019/00 G01N033/48 G01N033/50 C12N015/867. 22. 20030138807. 08 Aug 02. 24 Jul 03. UDP-galactose: beta-D-galactose-R 4-alpha-D-galactosyltransferase, alpha4Gal-T1. Clausen, Henrik, et al. 435/6; 435/193 435/320.1 435/325 435/69.1 435/7.1 530/388.26 536/23.2 C12Q001/68 G01N033/53 C07H021/04 C12P021/02 C12N005/06 C12N009/10 C07K016/40. 23. 20030051260. 06 Jan 99. 13 Mar 03. HMGI PROTEINS IN CANCER AND OBESITY. CHADA, KIRAN K., et al. 800/8; 800/13 800/14 800/15 800/16 800/17 800/18 800/19 800/21 800/22 800/23 800/24 800/25 A01K067/027 A01K067/033. 24. 20030037350. 05 Jun 02. 20 Feb 03. Novel nucleic acid sequences encoding a human ubiquitin protease, lipase, dynamin, short chain dehydrogenase, and ADAM-TS metalloprotease and uses therefor.

Record List Display Page 3 of 6

Glucksmann, Maria Alexandra, et al. 800/8; 435/183 435/320.1 435/325 435/69.1 536/23.2 A01K067/00 C07H021/04 C12N009/00 C12P021/02 C12N005/06. 25. 20030036074. 24 May 02. 20 Feb 03. Novel nucleic acid sequences encoding human transporters, a human atpase molecule, a human ubiquitin hydrolase-like molecule, a human ubiquitin conjugating enzyme-like molecule, and uses therefor. Glucksmann, Maria Alexandra, et al. 435/6; 435/199 435/226 435/320.1 435/325 435/69.1 530/350 536/23.2 C12Q001/68 C07H021/04 C12N009/22 C12N009/64 C12P021/02 C12N005/06. 26. 20020199211. 19 Feb 02. 26 Dec 02. WIP, a WASP-associated protein. Ramesh, Narayanaswamy, et al. 800/9; 800/18 A01K067/027. 27. 20020160386. 02 Nov 01. 31 Oct 02. Methods of using transporter-like molecules to treat pain and pain-related disorders. Goodearl, Andrew D.J., et al. 435/6; 435/7.1 C12Q001/68 G01N033/53. 28. 20020157119. 30 Aug 01. 24 Oct 02. Identification of activated receptors and ion channels. Beachy, Philip A., et al. 800/8; 435/194 435/320.1 435/354 435/6 435/7.1 530/350 A01K067/00 C12O001/68 G01N033/53 C12N009/12 C12P021/02 C12N005/06 C07K014/435 C07K014/72. 29. 20020152481. 25 Mar 02. 17 Oct 02. 23413, a novel human ubiquitin protease. Kapeller-Libermann, Rosana, et al. 800/8; 435/226 435/320.1 435/325 435/69.1 536/23.2 A01K067/00 C07H021/04 C12N009/64 C12P021/02 C12N005/06. 30. 20020142939. 12 Sep 01. 03 Oct 02. HMGI proteins in cancer and obesity. Chada, Kiran K., et al. 514/1; 800/18 A01K067/027 A61K031/00. 31. 20020127542. 01 Mar 02. 12 Sep 02. Pharmaceutical compositions for treating tumour diseases. Beug, Hartmut, et al. 435/4; 514/1 A61K031/00 C12Q001/00. 32. 20020115112. 15 Aug 01. 22 Aug 02. Neutrokine-alpha and Neutrokine-alpha splice variant. Yu, Guo-Liang, et al. 435/7.2; 424/145.1 530/388.23 C07K016/24 G01N033/567 G01N033/53 A61K039/395. 33. 20020086407. 05 Oct 01. 04 Jul 02. 23484, a novel human ubiquitin protease. Kapeller-Libermann, Rosana. 435/226; 435/320.1 435/325 435/69.1 536/23.2 C12N009/64 C07H021/04 C12P021/02 C12N005/06. 34. 20020051785. 20 Mar 01. 02 May 02. HER -2/neu overexpression abrogates growth inhibitory pathways. Slamon, Dennis J., et al. 424/145.1; 514/44 A61K039/395 A61K048/00. 35. 20020042679. 14 Dec 00. 11 Apr 02. Method of managing the chemotherapy of patients who are HIV positive based on the phenotypic drug sensitivity of human HIV strains. de Bethune, Marie-Pierre, et al. 702/19; 435/5 G01N033/48 C12Q001/70. 36. 20020031508. 17 May 01. 14 Mar 02. Methods for diagnosing and treating hemostatic disorders by modulating P-selectin activity. Wagner, Denisa D., et al. 424/94.63; 424/145.1 514/12 A61K038/48 A61K039/395 A61K038/17. 37. 20020028798. 20 Apr 01. 07 Mar 02. Irrigation solution and method for inhibition of pain and inflammation. Demopulos, Gregory A., et al. 514/210.2; 514/215 514/249 514/338 514/456 A61K031/4427 A61K031/4439 A61K031/55.

38. 20020028482. 20 Oct 98. 07 Mar 02. NIP45 HUMAN HOMOLOG. ZHOU, HONG, et al. 435/69.1; 435/320.1 435/325 435/7.1 512/12 530/350 530/387.1 536/23.5 C07H021/04 C12P021/06 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74 C12N005/00 C12N005/02 C07K001/00 C07K014/00 C07K017/00 C07K016/00 A61K007/46 G01N033/53. 39. 6812327. 22 Feb 00; 02 Nov 04. Neutrokine-alpha polypeptides. Yu; Guo-Liang, et al. 530/351; 424/198.1 424/85.1 435/69.5 530/300 530/350 530/399. A61K038/16 C07K002/00 C07K014/00 C07K014/52. 40. 6767541. 20 Mar 01; 27 Jul 04. HER-2/neu overexpression abrogates growth inhibitory pathways. Slamon; Dennis J., et al. 424/143.1; 424/130.1 424/133.1 424/141.1 424/142.1 424/152.1 424/155.1 424/156.1 424/172.1 424/174.1 514/2 530/387.1 530/387.3 530/387.7 530/388.1 530/388.15 530/388.2 530/388.22 530/388.8 530/388.85. A61K039/395 A61K038/18 A61K038/19 C07K016/30 C07K016/28. 41. 6756355. 07 May 97; 29 Jun 04. HMGI proteins in cancer and obesity. Chada; Kiran K., et al. 514/12; 435/4 435/6 435/7.1 514/2 530/350. A61K038/00 C12Q001/00. 42. 6720472. 06 Jan 99; 13 Apr 04. HMGI proteins in cancer and obesity. Chada; Kiran K., et al. 800/18; 800/22. A01K067/00. 43. 6696239. 20 Apr 00; 24 Feb 04. Comparative phenotype analysis for assessment of biological active compounds such as antimicrobials. Bochner; Barry. 435/4; 435/29 435/32 435/6 435/822. C12Q001/00 C12Q001/02 C12Q001/18 C12Q001/68 C12N001/00. 44. 6638718. 17 Mar 00; 28 Oct 03. Methods of screening for compounds active on staphylococcus aureus target genes. Benton; Bret, et al. 435/6; 435/69.1 436/501 436/63 514/2 514/44. C12Q001/68 C12P021/06 Q01N033/48 Q01N033/566 A01N037/18 A01N043/04. 45. 6635482. 08 Jun 00; 21 Oct 03. Monoclonal antibodies to membrane neutrokine-.alpha.. Yu; Guo-Liang, et al. 435/326; 435/328 435/331 435/4 530/387.1 530/387.3 530/387.9 530/388.1 530/388.15. C12N005/06 C12Q001/00 C07K016/00 C12P021/08. 46. 6630303. 17 Mar 00; 07 Oct 03. Methods of screening for compounds active on Staphylococcus aureus target genes. Benton; Bret, et al. 435/6; 435/69.1 436/501 436/63 514/2 514/44. C12Q001/68 C12P021/06 Q01N033/48 Q01N033/566 A01N037/18 A01N043/04. 47. 6573057. 02 Nov 01; 03 Jun 03. Methods of using transporter-like molecules to treat pain and pain-related disorders. Goodearl; Andrew D. J., et al. 435/7.1; 530/350. G01M033/53 C07K014/00. 48. 6562579. 08 Jun 00; 13 May 03. Diagnostic methods using antibodies to Neutrokine-alpha. Yu; Guo-Liang, et al. 435/7.1; 435/7.2 530/350 530/387.9 530/388.1 530/388.23 530/389.1 530/391.3. G01N033/53 C07K016/24. 49. 6528251. 14 Dec 00; 04 Mar 03. Method of managing the chemotherapy of patients who are HIV positive based on the phenotypic drug sensitivity of human HIV strains. de Bethune; Marie-Pierre, et al. 435/5; 435/252.1 435/320.1 514/44 536/23.1. C12Q001/70. 50. 6514746. 20 May 98; 04 Feb 03. Staphylococcus aureus histidine protein kinase essential genes. Benton; Bret, et al. 435/252.3; 435/320.1 536/23.1 536/24.3 536/24.32 536/24.33. C12N001/20.

51. 6492332. 11 Sep 00; 10 Dec 02. Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation. Demopulos; Gregory A., et al. 514/12; 514/217 514/226.2 514/25 514/254.06 514/259.1 514/263.1 514/266.1 514/280 514/288 514/317 514/327 514/353 514/356 514/397 514/413 514/415 514/509 514/619 514/654 514/680. A61K038/00 A61K031/70 A61K031/55 A61K031/54 A61K031/495 A61K031/505. 52. 6451994. 27 Sep 99; 17 Sep 02. 23413, a novel human ubiquitin protease. Kapeller-Libermann; Rosana, et al. 536/23.5; 536/23.1 536/24.3 536/24.31. C07H021/02 C07H021/04. 53. 6436631. 02 Feb 01; 20 Aug 02. Comparative phenotype analysis for assessment of biologically active compounds such as antimicrobials. Bochner; Barry. 435/4; 435/29 435/32 435/822 435/975. C12Q001/00 C12Q001/02 C12Q001/18 C12N001/00. 54. 6403770. 08 Jun 00; 11 Jun 02. Antibodies to neutrokine-alpha. Yu; Guo-Liang, et al. 530/387.<del>3; 435/69.5</del> 435/7.1 530/300 530/324 530/351 530/388.1 530/388.23. C07K016/00 C12P021/08 C12P021/02 G01N035/53. 55. 6383733. 16 Feb 99; 07 May 02. Methods of screening for pharmacologically active compounds for the treatment of tumour diseases. Beug; Hartmut, et al. 435/4; 435/320.1 435/325 435/7.1 435/7.2 435/7.21 436/63 436/64. C12Q001/00 G01N033/53 G01N033/567 C12N015/00 C12N015/09. 56. 6329171. 30 Sep 99; 11 Dec 01. 23484, A novel human ubiquitin protease. Kapeller-Libermann; Rosana. 435/69.1; 435/252.3 435/325 435/455 435/471 536/23.1 536/23.5. C12N015/12 C12N015/63 C12N015/85 C07H021/00. 57. 6228588. 09 Mar 99; 08 May 01. Methods of screening for compounds active on Staphylococcus aureus target genes. Benton; Bret, et al. 435/6; 435/69.1 514/2 514/44. C12Q001/68. 58. 6221578. 24 Jul 98; 24 Apr 01. Method of managing the chemotherapy of patients who are HIV positive based on the phenotypic drug sensitivity of human HIV strains, de Bethune; Marie-Pierre, et al. 435/5; 435/6 536/23.1 536/24.1. C12Q001/70 C12Q001/68 C07H021/02 C07H021/04. 59. 6187541. 09 Mar 99; 13 Feb 01. Methods of screening for compounds active on staphylococcus aureus target genes. Benton; Bret, et al. 435/6; 435/69.1 514/2 514/44. C12O001/68. 60. 6037123. 13 Sep 96; 14 Mar 00. Methods of screening for compounds active on Staphylococcus aureus target genes. Benton; Bret, et al. 435/6; 435/69.1 436/501 514/2 514/44. C12Q001/68. 61. 5877007. 07 Jun 95; 02 Mar 99. Method of screening for protein inhibitors and activators. Housey; Gerard. 435/252.3; 435/29 435/69.1 435/7.4 435/7.71. C12N001/21 C12N001/00 C12P021/02 G01N033/573. 62. 5688655. 17 Mar 95; 18 Nov 97. Method of screening for protein inhibitors and activators. Housey; Gerard. 435/7.21; 435/29. C12Q001/02. 63. 5266464. 10 Aug 89; 30 Nov 93. Method of screening for protein inhibitors and activators. Housey; Gerard. 435/29; 435/358. C12Q001/02.



Terms	Documents
L4 and phenotyp\$ near5 respons\$	63

Prev Page Go to Doc# Next Page



Day: Thursday

Date: 1/6/2005 Time: 17:26:31

# **Inventor Name Search**

Enter the **first few letters** of the Inventor's Last Name. Additionally, enter the **first few letters** of the Inventor's First name.

Last Name	First Name	
housey	gerard	Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page